More than 25% of older adults (age ≥75 years) have diabetes and may be at risk of adverse events related to treatment. The aim of this study was to assess the prevalence of intensive glycaemic control in this group, potential overtreatment among older adults and the impact of overtreatment on the risk of serious events.
We conducted a retrospective, population-based cohort study of community-dwelling older adults in Ontario using administrative data. Participants were ≥75 years of age with diagnosed diabetes treated with at least one anti-hyperglycaemic agent between 2014 and 2015. Individuals were categorised as having intensive or conservative glycaemic control (HbA1c <53 mmol/mol [<7%] or 54–69 mmol/mol [7.1–8.5%], respectively), and as undergoing treatment with high-risk (i.e. insulin, sulfonylureas) or low-risk (other) agents. We measured the composite risk of emergency department visits, hospitalisations, or death within 30 days of reaching intensive glycaemic control with high-risk agents.
Among 108,620 older adults with diagnosed diabetes in Ontario, the mean (± SD) age was 80.6 (±4.5) years, 49.7% were female, and mean (± SD) diabetes duration was 13.7 (±6.3) years. Overall, 61% of individuals were treated to intensive glycaemic control and 21.6% were treated to intensive control using high-risk agents. Using inverse probability treatment weighting with propensity scores, intensive control with high-risk agents was associated with nearly 50% increased risk of the composite outcome compared with conservative glycaemic control with low-risk agents (RR 1.49, 95% CI 1.08, 2.05).
Our findings underscore the need to re-evaluate glycaemic targets in older adults and to reconsider the use of anti-hyperglycaemic medications that may lead to hypoglycaemia, especially in setting of intensive glycaemic control.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
The dataset from this study is held securely in coded form at ICES. While data sharing agreements prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS. The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.
Inverse probability of treatment weighting
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053. https://doi.org/10.2337/diacare.27.5.1047
Lipscombe LL, Hux JE (2007) Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 369(9563):750–756. https://doi.org/10.1016/S0140-6736(07)60361-4
Cheng YJ, Imperatore G, Geiss LS et al (2013) Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010. Diabetes Care 36(9):2690–2696. https://doi.org/10.2337/dc12-2074
(1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837–853. https://doi.org/10.1128/AAMCol.14Aug.1998
Boucher BJ (1998) Inadequate vitamin D status: does it contribute to the disorders comprising syndrome ‘X’? Br J Nutr 79(4):315–327
Group AC, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572. https://doi.org/10.1056/NEJMoa0802987
Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365(21):2002–2012. https://doi.org/10.1056/NEJMsa1103053
Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA (2015) Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 175(3):356–362. https://doi.org/10.1001/jamainternmed.2014.7345
Bolli G, de Feo P, Compagnucci P et al (1983) Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32(2):134–141. https://doi.org/10.2337/diab.32.2.134
Signorovitch JE, Macaulay D, Diener M et al (2013) Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab 15(4):335–341. https://doi.org/10.1111/dom.12031
Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347:f4533. https://doi.org/10.1136/bmj.f4533
Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK (2015) Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38(2):316–322. https://doi.org/10.2337/dc14-0920
Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301(15):1565–1572. https://doi.org/10.1001/jama.2009.460
Bonds DE, Miller ME, Bergenstal RM et al (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909. https://doi.org/10.1136/bmj.b4909
Group AS, Gerstein HC, Miller ME et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364(9):818–828. https://doi.org/10.1056/NEJMoa1006524
Hayward RA, Reaven PD, Wiitala WL et al (2015) Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372(23):2197–2206. https://doi.org/10.1056/NEJMoa1414266
Zoungas S, Chalmers J, Neal B et al (2014) Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371(15):1392–1406. https://doi.org/10.1056/NEJMoa1407963
Lipska KJ, Krumholz H, Soones T, Lee SJ (2016) Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA 315(10):1034–1045. https://doi.org/10.1001/jama.2016.0299
Diabetes Canada Clinical Practice Guidelines Expert C, Meneilly GS, Knip A et al (2018) Diabetes in older people. Can J Diabetes 42(Suppl 1):S283–S295. https://doi.org/10.1016/j.jcjd.2017.10.021
LeRoith D, Biessels GJ, Braithwaite SS et al (2019) Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 104(5):1520–1574. https://doi.org/10.1210/jc.2019-00198
Arnold SV, Lipska KJ, Wang J, Seman L, Mehta SN, Kosiborod M (2018) Use of intensive glycemic management in older adults with diabetes mellitus. J Am Geriatr Soc 66(6):1190–1194. https://doi.org/10.1111/jgs.15335
Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM (2014) Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med 174(2):259–268. https://doi.org/10.1001/jamainternmed.2013.12963
Muller N, Khunti K, Kuss O et al (2017) Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta Diabetol 54(2):209–214. https://doi.org/10.1007/s00592-016-0939-9
McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND (2016) Intensive treatment and severe hypoglycemia among adults with type 2 diabetes. JAMA Intern Med 176(7):969–978. https://doi.org/10.1001/jamainternmed.2016.2275
Mahoney GK, Henk HJ, McCoy RG (2019) Severe hypoglycemia attributable to intensive glucose-lowering therapy among US adults with diabetes: population-based modeling study, 2011-2014. Mayo Clin Proc. https://doi.org/10.1016/j.mayocp.2019.02.028
Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298(22):2634–2643. https://doi.org/10.1001/jama.298.22.2634
Hux JE, Ivis F, Flintoft V, Bica A (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25(3):512–516. https://doi.org/10.2337/diacare.25.3.512
Khan H, Lasker SS, Chowdhury TA (2011) Exploring reasons for very poor glycaemic control in patients with type 2 diabetes. Prim Care Diabetes 5(4):251–255. https://doi.org/10.1016/j.pcd.2011.07.001
Reid RJ, Roos NP, MacWilliam L, Frohlich N, Black C (2002) Assessing population health care need using a claims-based ACG morbidity measure: a validation analysis in the Province of Manitoba. Health Serv Res 37(5):1345–1364. https://doi.org/10.1111/1475-6773.01029
King N, King M (2014) The Ontario cancer registry moves to the 21st century. Cancer Care Ontario, Toronto
Jaakkimainen RL, Bronskill SE, Tierney MC et al (2016) Identification of physician-diagnosed Alzheimer’s disease and related dementias in population-based administrative data: a validation study using family physicians’ electronic medical records. J Alzheimers Dis 54(1):337–349. https://doi.org/10.3233/JAD-160105
Schultz SE, Rothwell DM, Chen Z, Tu K (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33(3):160–166
Tam DY, Dharma C, Rocha R et al (2020) Long-term survival after surgical or percutaneous revascularization in patients with diabetes and multivessel coronary disease. J Am Coll Cardiol 76(10):1153–1164
Singh SM, Abdel-Qadir H, Pang A et al (2020) Population trends in all-cause mortality and cause specific–death with incident atrial fibrillation. J Am Heart Assoc 9(19):e016810. https://doi.org/10.1016/j.compbiomed.2020.104185
Yu AY, Austin PC, Rashid M et al (2020) Deriving a passive surveillance stroke severity indicator from routinely collected administrative data: the PaSSV Indicator. Circ Cardiovasc Qual Outcomes 13(2):e006269
Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399–424. https://doi.org/10.1080/00273171.2011.568786
Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661–3679. https://doi.org/10.1002/sim.6607
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139. https://doi.org/10.1056/NEJMoa0808431
Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR (2015) Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. J Oncol Pract 11(6):491–497. https://doi.org/10.1200/JOP.2015.004929
Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30(2):389–394. https://doi.org/10.2337/dc06-1789
Hubbard R, Andrew M, Fallah N, Rockwood K (2010) Comparison of the prognostic importance of diagnosed diabetes, co-morbidity and frailty in older people. Diabet Med 27(5):603–606. https://doi.org/10.1111/j.1464-5491.2010.02977.x
Hambling CE, Seidu SI, Davies MJ, Khunti K (2017) Older people with type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabet Med 34(9):1219–1227. https://doi.org/10.1111/dme.13380
American Diabetes Association (2019) 12. Older adults: standards of medical care in diabetes – 2019. Diabetes Care 42(Suppl 1):S139–S147. https://doi.org/10.2337/dc19-S012
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; Meneilly GS, Knip A, Tessier D (2013) Diabetes in the elderly. Can J Diabetes 37:184–190
Yu CH, Gall Casey C, Ke C, Lebovic G, Straus SE (2019) Process evaluation of the Diabetes Canada guidelines dissemination strategy using the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework. Can J Diabetes 43(4):263–270.e9. https://doi.org/10.1016/j.jcjd.2018.08.189
Yu CH, Lillie E, Mascarenhas-Johnson A, Gall Casey C, Straus SE (2018) Impact of the Canadian Diabetes Association guideline dissemination strategy on clinician knowledge and behaviour change outcomes. Diabetes Res Clin Pract 140:314–323. https://doi.org/10.1016/j.diabres.2018.02.041
Markovitz AA, Hofer TP, Froehlich W et al (2018) An examination of deintensification recommendations in clinical practice guidelines: stepping up or scaling back? JAMA Intern Med 178(3):414–416. https://doi.org/10.1001/jamainternmed.2017.7198
Caverly TJ, Fagerlin A, Zikmund-Fisher BJ et al (2015) Appropriate prescribing for patients with diabetes at high risk for hypoglycemia: national survey of veterans affairs health care professionals. JAMA Intern Med 175(12):1994–1996. https://doi.org/10.1001/jamainternmed.2015.5950
Godolphin W (2009) Shared decision-making. Healthc Q 12 Spec No Patient: e186–190
Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed in the material are those of the authors, and not necessarily those of CIHI. In addition, we thank IMS Brogan Inc. for use of their Drug Information Database.
The authors wish to acknowledge the assistance of Vaidehi Misra (Women’s College Research Institute, Toronto, ON, Canada) for her assistance with editing and formatting the manuscript.
Authors’ relationships and activities
The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
This study was supported by a grant from the Canadian Institutes of Health Research (CIHR) (1018890). LLL is supported by a Diabetes Investigator Award from Diabetes Canada. PCA is supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation. PAR holds the RTO/ERO Chair in Geriatric Medicine from the University of Toronto. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). ICES is an independent, non-profit research institute, the legal status of which under Ontario’s health information privacy law allows it to collect and analyse healthcare and demographic data, without consent, for health system evaluation and improvement. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lega, I.C., Campitelli, M.A., Austin, P.C. et al. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia (2021). https://doi.org/10.1007/s00125-020-05370-7
- Diabetes overtreatment
- Healthcare delivery
- Insulin secretagogues
- Insulin therapy
- Intensive glycaemic control
- Older adults